Microbiome Influences on Urogenital Cancer Development

The human microbiome exerts a substantial influence on the development, progression and treatment response of urogenital cancers, notably prostate and bladder malignancies. In the prostate context, gut microbes can modulate systemic inflammation, hormone metabolism and immune surveillance, thereby shaping tumour growth and resistance to therapy. In bladder cancer, the urinary microbial community—or urobiome—contributes to a proinflammatory microenvironment and perturbs fatty acid metabolism, with potential consequences for early detection and recurrence monitoring. Across both sites, microbial dysbiosis alters short-chain fatty acid production, lipopolysaccharide translocation and immune cell activation, linking local‐site and distal gut communities to tumour initiation and progression. Understanding these cross-talk mechanisms opens avenues for novel diagnostics, dietary or microbial interventions and precision therapeutics that harness or reshape the host–microbe interface.

Research from Nature Portfolio

Recent studies have delineated key microbial signatures and functional pathways in urogenital cancer. A 2024 investigation demonstrated that reduced gut microbial diversity correlates with increased prostate tumour burden. Fecal microbiota transplantation from high-volume patients to mice accelerated tumour growth, pinpointing microbial enzymes that metabolise long-chain fatty acids. Dietary supplementation with omega-3 lipid derivatives attenuated tumour progression in preclinical models and corresponded with shifts in butyrate-producing bacteria in patients. Earlier foundational work characterised the urinary microbiome in bladder cancer, identifying an enrichment of Fusobacterium in patient samples compared with healthy controls—suggesting a direct microbial contribution to tumourigenesis. Complementing this, a comparative analysis of bladder tissue and urine samples revealed “five suspect genera” (including Akkermansia and Klebsiella) that were over-represented in tumour mucosa, highlighting the potential of tissue-associated microbiota as more accurate biomarkers than voided urine alone.

Microbiome Influences on Urogenital Cancer Development publication trend

The graph below shows the total number of articles in microbiome influences on urogenital cancer development across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha diversity: A measure of microbial richness and evenness within a single sample or ecosystem.

Dysbiosis: An imbalance in microbial community composition that can disrupt host homeostasis and contribute to disease.

Short-chain fatty acids (SCFAs): Microbial fermentation products (e.g., butyrate, propionate) that influence host immunity, inflammation and epithelial integrity.

Fecal microbiota transplantation (FMT): The transfer of stool‐derived microbial communities from a donor to a recipient to modify gut ecology and host physiology.

Urobiome: The community of microorganisms inhabiting the urinary tract, distinct from gastrointestinal and skin microbiota.

References

1. The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. Nature Communications (2024).
2. Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer. Journal of Experimental & Clinical Cancer Research (2024).
3. Urinary microbiome dysbiosis is associated with an inflammatory environment and perturbed fatty acids metabolism in the pathogenesis of bladder cancer. Journal of Translational Medicine (2024).
4. The urinary microbiome associated with bladder cancer. Scientific Reports (2018).
5. Dysbiosis signatures of the microbial profile in tissue from bladder cancer. Cancer Medicine (2019).
6. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome (2022).